S-(5-acetamido-2-hydroxyphenyl)-N-acetyl-L-cysteine : An S-substituted N-acetyl-L-cysteine in which the S-substitutuent is specified as 5-acetamido-2-hydroxyphenyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 83967 |
| CHEBI ID | 133435 |
| MeSH ID | M0138580 |
| Synonym |
|---|
| acetaminophen mercapturate |
| n-acetyl-l-cysteine s-acetaminophen conjugate |
| n-acetyl-s-(5-(acetylamino)-2-hydroxyphenyl)-l-cysteine |
| paracetamol n-acetyl-l-cysteine conjugate |
| acetaminophen mercapturic acid |
| s-(5-acetamido-2-hydroxyphenyl)-n-acetyl-l-cysteine |
| CHEBI:133435 |
| acetaminophen n-acetyl-l-cysteine conjugate |
| n-acetyl-l-cysteine s-paracetamol conjugate |
| 3-(n-acetyl-l-cystein-s-yl)acetaminophen |
| l-cysteine, n-acetyl-s-[5-(acetylamino)-2-hydroxyphenyl]- |
| (2r)-2-acetamido-3-(5-acetamido-2-hydroxyphenyl)sulfanylpropanoic acid |
| r86seu3g6u , |
| unii-r86seu3g6u |
| l-cysteine, n-acetyl-s-(5-(acetylamino)-2-hydroxyphenyl)- |
| 3-((5-acetamido-2-hydroxyphenyl)thio)-n-acetylalanine |
| acetaminophen-2-mercapturate |
| n-acetyl-2-(n-acetyl-l-s-cysteinyl)-4-aminophenol |
| DVPRQNKJGQEICH-JTQLQIEISA-N |
| n-acetyl[5-(acetylamino)-2-hydroxyphenyl]cysteine # |
| AKOS028112412 |
| (2r)-2-acetamido-3-(5-acetamido-2-hydroxy-phenyl)sulfanyl-propanoic acid |
| 2-hydroxyphenyl)sulfanylpropanoic acid |
| DTXSID30966766 |
| n-(1-hydroxyethylidene)-s-{2-hydroxy-5-[(1-hydroxyethylidene)amino]phenyl}cysteine |
| Q27287959 |
| 3-(n-acetyl-l-cystein-s-yl) acetaminophen, sodium salt |
| PD057008 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Since the major nontoxic pathway (glucuronide) and the toxic pathway (as measured by mercapturate) decreased to a similar extent, the data indicate that the anomalous lack of protection cannot be explained on the basis of altered metabolic disposition of the drug." | ( Anomalous susceptibility of the fasted hamster to acetaminophen hepatotoxicity. Jollow, DJ; Miller, MG; Price, VF, 1986) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetic (PK) profile of a drug is influenced by several factors, which can lead to a suboptimal dosing regimen in specific patient populations." | ( Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients. Boffel, L; De Baerdemaeker, L; Delahaye, L; Stove, CP, 2022) | 0.72 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted." | ( The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. Martin, U; Prescott, LF; Temple, RM; Winney, RJ, 1993) | 0.29 |
| "The pharmacokinetic (PK) profile of a drug is influenced by several factors, which can lead to a suboptimal dosing regimen in specific patient populations." | ( Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients. Boffel, L; De Baerdemaeker, L; Delahaye, L; Stove, CP, 2022) | 0.72 |
| Role | Description |
|---|---|
| drug metabolite | null |
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| rat metabolite | Any mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| organic sulfide | Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| S-substituted N-acetyl-L-cysteine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||